As part of this initiative, all patients with suspected HAE undergo comprehensive diagnostic evaluation, including assessment of both the quantitative and functional levels of C1 inhibitor, measurement of C3 levels, and genetic testing for SERPING1 mutations. This evidence concerns the gene SERPING1 and hereditary angioedema.